CU20200051A7 - Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 - Google Patents
Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5Info
- Publication number
- CU20200051A7 CU20200051A7 CU2020000051A CU20200051A CU20200051A7 CU 20200051 A7 CU20200051 A7 CU 20200051A7 CU 2020000051 A CU2020000051 A CU 2020000051A CU 20200051 A CU20200051 A CU 20200051A CU 20200051 A7 CU20200051 A7 CU 20200051A7
- Authority
- CU
- Cuba
- Prior art keywords
- bicyclic heterocyclic
- prmt5 inhibitors
- components replaced
- heterocyclic components
- replaced
- Prior art date
Links
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 title 1
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>La invención se refiere a compuestos heterocíclicos bicíclicos sustituidos de fórmula (I), a sales farmacéuticamente aceptables de los mismos y a composiciones farmacéuticas que comprenden al menos un compuesto de fórmula (I).</p>
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721044886 | 2017-12-13 | ||
| IN201821024634 | 2018-07-02 | ||
| IN201821040029 | 2018-10-23 | ||
| PCT/IB2018/060015 WO2019116302A1 (en) | 2017-12-13 | 2018-12-13 | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20200051A7 true CU20200051A7 (es) | 2021-03-11 |
| CU24621B1 CU24621B1 (es) | 2022-09-08 |
Family
ID=65036860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2020000051A CU24621B1 (es) | 2017-12-13 | 2018-12-13 | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11459330B2 (es) |
| EP (1) | EP3724190B1 (es) |
| JP (1) | JP7282778B2 (es) |
| KR (1) | KR102708147B1 (es) |
| CN (1) | CN111712498B (es) |
| AU (1) | AU2018385664B2 (es) |
| BR (1) | BR112020011746A2 (es) |
| CA (1) | CA3085259A1 (es) |
| CL (1) | CL2020001576A1 (es) |
| CR (1) | CR20200263A (es) |
| CU (1) | CU24621B1 (es) |
| CY (1) | CY1125784T1 (es) |
| DK (1) | DK3724190T3 (es) |
| ES (1) | ES2927860T3 (es) |
| GE (2) | GEAP202115385A (es) |
| HR (1) | HRP20221207T1 (es) |
| HU (1) | HUE059945T2 (es) |
| IL (1) | IL274936B2 (es) |
| LT (1) | LT3724190T (es) |
| MX (1) | MX2020006181A (es) |
| MY (1) | MY199124A (es) |
| PE (1) | PE20211444A1 (es) |
| PH (1) | PH12020550881A1 (es) |
| PL (1) | PL3724190T3 (es) |
| PT (1) | PT3724190T (es) |
| RS (1) | RS63623B1 (es) |
| SG (1) | SG11202004934QA (es) |
| SM (1) | SMT202200396T1 (es) |
| UA (1) | UA126349C2 (es) |
| WO (1) | WO2019116302A1 (es) |
| ZA (1) | ZA202003528B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CA3114672A1 (en) | 2018-10-05 | 2020-04-23 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| MA55556A (fr) * | 2019-04-02 | 2022-02-09 | Aligos Therapeutics Inc | Composés ciblant prmt5 |
| US11884672B2 (en) | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| CN114126614A (zh) * | 2019-05-30 | 2022-03-01 | 安杰斯制药公司 | 作为prmt5抑制剂的杂环化合物 |
| HUE064493T2 (hu) * | 2019-06-10 | 2024-03-28 | Lupin Ltd | PRMT5 inhibitorok |
| KR20220086628A (ko) | 2019-10-22 | 2022-06-23 | 루핀 리미티드 | Prmt5 저해제의 약학적 조합물 |
| US20220372040A1 (en) * | 2019-10-25 | 2022-11-24 | Accent Therapeutics, Inc. | Mettl3 modulators |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| EP4069698A1 (en) | 2019-12-03 | 2022-10-12 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| US20220112194A1 (en) * | 2020-04-01 | 2022-04-14 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
| JP7732999B2 (ja) | 2020-04-03 | 2025-09-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | アルファ１－アンチトリプシンのモジュレーター |
| CN115697969A (zh) * | 2020-04-03 | 2023-02-03 | 弗特克斯药品有限公司 | 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的7-或8-羟基-异喹啉和7-或8-羟基-喹啉衍生物 |
| WO2022026892A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| CR20230402A (es) | 2021-01-19 | 2023-11-21 | Lupin Ltd | Combinaciones farmacéuticas de inhibidores de sos1 para tratar o prevenir cancer |
| CN113234079B (zh) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | 用作prmt5抑制剂的核苷类似物 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004009574A1 (en) | 2002-07-22 | 2004-01-29 | Novartis Ag | Synthesis of discodermolide |
| WO2005016878A2 (en) | 2003-08-13 | 2005-02-24 | Isis Pharmaceuticals, Inc. | METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
| JP2009539815A (ja) | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物 |
| US8299256B2 (en) | 2007-03-08 | 2012-10-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
| FR2926556B1 (fr) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| EP2331543A4 (en) * | 2008-09-26 | 2013-06-19 | Agency Science Tech & Res | 3-deazaneplanocin DERIVATIVES |
| WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
| GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
| ES2689103T3 (es) | 2010-06-30 | 2018-11-08 | Fujifilm Corporation | Nuevo derivado de nicotinamida o sal del mismo |
| WO2012037108A1 (en) | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
| WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
| EP2744333B1 (en) | 2011-08-19 | 2016-10-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Fatty acid synthase inhibitors |
| JP6182593B2 (ja) * | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
| PT2861604T (pt) | 2012-06-08 | 2017-05-05 | Gilead Sciences Inc | Inibidores macrocíclicos de vírus flaviridae |
| WO2014008223A2 (en) | 2012-07-03 | 2014-01-09 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
| JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| CA2899363A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US9745291B2 (en) | 2012-12-21 | 2017-08-29 | Epizyme, Inc. | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| CA2894126A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| DK2935222T3 (en) | 2012-12-21 | 2019-01-07 | Epizyme Inc | PRMT5 INHIBITORS AND APPLICATIONS THEREOF |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| CA2942833A1 (en) | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
| EP3055290B1 (en) | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
| MX374574B (es) | 2014-05-22 | 2025-03-06 | Hoffmann La Roche | Derivados indolin-2-ona y 1,3-dihidro-pirrol[3,2-c]piridin-2-ona. |
| SMT202100260T1 (it) | 2014-06-25 | 2021-07-12 | Glaxosmithkline Ip Dev Ltd | Sali cristallini di (s)-6-((1-acetilpiperidin-4-il)ammino)-n-(3-(3,4-diidroisochinolin-2(1h)-il)-2-idrossipropil) pirimidin-4-carbossammide. |
| US20170210751A1 (en) | 2014-06-25 | 2017-07-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2016022605A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2016034673A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
| EP3189048B1 (en) | 2014-09-03 | 2021-03-17 | Ctxt Pty Ltd | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| EP3191592A1 (en) | 2014-09-11 | 2017-07-19 | Novartis AG | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
| MX2017010844A (es) | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
| EP3268044A2 (en) | 2015-03-11 | 2018-01-17 | The Broad Institute Inc. | Prmt5 inhibitors for the treatment of cancer with reduced mtap activty |
| AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI870767B (zh) * | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
-
2018
- 2018-12-13 SM SM20220396T patent/SMT202200396T1/it unknown
- 2018-12-13 MX MX2020006181A patent/MX2020006181A/es unknown
- 2018-12-13 HU HUE18836520A patent/HUE059945T2/hu unknown
- 2018-12-13 DK DK18836520.9T patent/DK3724190T3/da active
- 2018-12-13 KR KR1020207019844A patent/KR102708147B1/ko active Active
- 2018-12-13 ES ES18836520T patent/ES2927860T3/es active Active
- 2018-12-13 WO PCT/IB2018/060015 patent/WO2019116302A1/en not_active Ceased
- 2018-12-13 CR CR20200263A patent/CR20200263A/es unknown
- 2018-12-13 GE GEAP202115385A patent/GEAP202115385A/en unknown
- 2018-12-13 GE GEAP201815385A patent/GEP20227359B/en unknown
- 2018-12-13 PL PL18836520.9T patent/PL3724190T3/pl unknown
- 2018-12-13 HR HRP20221207TT patent/HRP20221207T1/hr unknown
- 2018-12-13 EP EP18836520.9A patent/EP3724190B1/en active Active
- 2018-12-13 LT LTEPPCT/IB2018/060015T patent/LT3724190T/lt unknown
- 2018-12-13 RS RS20220931A patent/RS63623B1/sr unknown
- 2018-12-13 UA UAA202004140A patent/UA126349C2/uk unknown
- 2018-12-13 MY MYPI2020002798A patent/MY199124A/en unknown
- 2018-12-13 JP JP2020532614A patent/JP7282778B2/ja active Active
- 2018-12-13 US US16/772,959 patent/US11459330B2/en active Active
- 2018-12-13 SG SG11202004934QA patent/SG11202004934QA/en unknown
- 2018-12-13 IL IL274936A patent/IL274936B2/en unknown
- 2018-12-13 PT PT188365209T patent/PT3724190T/pt unknown
- 2018-12-13 BR BR112020011746-3A patent/BR112020011746A2/pt active IP Right Grant
- 2018-12-13 AU AU2018385664A patent/AU2018385664B2/en active Active
- 2018-12-13 CN CN201880089329.6A patent/CN111712498B/zh active Active
- 2018-12-13 CU CU2020000051A patent/CU24621B1/es unknown
- 2018-12-13 CA CA3085259A patent/CA3085259A1/en active Pending
- 2018-12-13 PE PE2020000761A patent/PE20211444A1/es unknown
-
2020
- 2020-06-06 PH PH12020550881A patent/PH12020550881A1/en unknown
- 2020-06-11 CL CL2020001576A patent/CL2020001576A1/es unknown
- 2020-06-12 ZA ZA2020/03528A patent/ZA202003528B/en unknown
-
2022
- 2022-05-06 US US17/738,370 patent/US11952380B2/en active Active
- 2022-09-30 CY CY20221100650T patent/CY1125784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20200051A7 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
| CY1125359T1 (el) | Νεα υποκατεστημενα με 6-6 δικυκλικο αρωματικο δακτυλιο νουκλεοσιδικα αναλογα για χρηση ως αναστολεις prmt5 | |
| MX2018003432A (es) | Compuestos heterociclicos y usos de los mismos. | |
| CU20210009A7 (es) | Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3) | |
| CU20180019A7 (es) | Derivados de heteroarilo como inhibidores de parp | |
| MX386103B (es) | Inhibidores de mcl-1 y metodos de uso de los mismos. | |
| DOP2016000094A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4. | |
| MX376271B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| CR20150045A (es) | Inhibidores de hepatitis c | |
| SV2016005137A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| CU20220005A7 (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
| EA201691625A1 (ru) | Ароматические гетероциклические соединения как противовоспалительные соединения | |
| UY35300A (es) | Formulación de combinación de dos compuestos antivirales | |
| EA201792021A1 (ru) | Ингибитор jak | |
| CO7131360A2 (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| CL2017003340A1 (es) | Compuestos inhibidores de serina/treonina-proteína cinasa (tbk)/inhibidor de cinasa de factor nuclear kappa-b subunidad epsilon (ikk-epsilon) y sus usos de los mismos | |
| MX394835B (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| MX2017016619A (es) | Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos. | |
| CU20180028A7 (es) | DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
| JOP20200030B1 (ar) | مركب خماسي الحلقة | |
| EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека |